Searched for
AUROBINDO PHARMA FACILITY
Indian pharma firms gear up to supply key cancer drug to USIndian drugmakers are stepping up to help the US combat a critical shortage of ifosfamide injection, a vital chemotherapy drug. Leading com...- Aurobindo Pharma US gets FTC nod for $250 million acquisition of Lannett CompanyAurobindo Pharma's US arm has secured Federal Trade Commission approval for its $250 million acquisition of Lannett Company. This strategic...
- Stocks in news: Rajesh Exports, Lenskart, Suzlon Energy, Aurobindo Pharma, Tata MotorsIndian markets saw volatility and closed lower on Wednesday. Key companies are in focus due to significant developments. SoftBank reduced i...
- Pharma exports to US seen muted this yearIndian pharma exports to the US face a subdued outlook this year. Policy uncertainties, falling generic prices, and regional conflicts are ...
- Aurobindo Pharma enters biologics contract manufacturing with Rs 1,200-crore Telangana facilityAurobindo Pharma has launched TheraNym, a major biologics manufacturing plant in Telangana. This facility will produce biologic medicines f...
- Pharma Q4 outlook mixed: Hospitals steady, generics face revlimid dragIndian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...
- AstraZeneca India plans to sell 64-acre Bengaluru site for Rs 3,400 croreThe land parcel, expected to fetch about ₹3,400 crore for AstraZeneca Pharma India, has drawn interest from developers including the Sattva...
- Market bets on Aurobindo as Europe, US sales show uptickAurobindo Pharma stock is performing well. Sales in Europe are improving. New products are launching in the US. The company is also develop...
- Aurobindo Pharma shares in focus after fire at Andhra Pradesh facility; operations paused for 20-25 daysAurobindo Pharma reported a fire at its Penicillin-G facility in Kakinada SEZ, damaging ancillary equipment but sparing core infrastructure...
- Aurobindo Pharma shares plunge over 6% after USFDA warning letter for subsidiaryAuroLife Pharma, a wholly-owned step-down subsidiary of the company, has received a warning letter from the United States Food and Drug Adm...
- Aurobindo Pharma arm's New Jersey unit gets warning letter from USFDAThis follows the earlier letter dated June 4, 2020, issuing an OAI (Official Action Indicated) status for this facility.
- Aurobindo Pharma gets VAI classification from USFDA for Hyderabad unitAs per the USFDA, a VAI inspection classification indicates that although investigators found and documented objectionable conditions durin...
- Aurobindo Pharma gets warning letter from USFDA for Andhra Pradesh unitThe drug firm, however, did not provide any details of the contents of the warning letter received from the regulator.
- Aurobindo Pharma arm enters pact to form JV in China with Luoxin"The percentage of shareholding in the joint venture company will be 30 per cent and 70 per cent between Helix and Luoxin," Aurobindo Pharm...
- USFDA team finds 'female mosquito' in Aurobindo Pharma's facility during inspectionThe American health regulator has issued nine observations after inspecting the drug maker's Unit 4 formulation facility near Hyderabad in ...
- Aurobindo Pharma's unit gets 9 USFDA observationsUSFDA has conducted an inspection at the company's unit 4, a formulation manufacturing facility in Hyderabad from February 12 to February 2...
- USFDA inspects two units of Aurobindo Pharma; makes observationsAurobindo Pharma said two of its facilities have undergone inspection by US health regulator USFDA, which has issued observations for one u...
- USFDA lifts import alert on Aurobindo Pharma's Hyderabad facilityUSFDA has lifted the import alert for non-sterile products manufactured at Unit-VI cephalosporin facility based in Hyderabad.
- Aurobindo Pharma planning to challenge SPCB orderAurobindo Pharma which has been served notice to shut down its facilities by Andhra Pradesh Pollution Control Board for allegedly violating...
- Aurobindo Q1 net dips 69 pc to Rs 51 crDrug maker Aurobindo Pharma said its consolidated net profit declined 69.08 per cent to Rs 51.50 crore for the first quarter ended June 30,...
Load More
